|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ING4 |
Gene summary for ING4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ING4 | Gene ID | 51147 |
| Gene name | inhibitor of growth family member 4 | |
| Gene Alias | my036 | |
| Cytomap | 12p13.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UNL4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51147 | ING4 | LZE7T | Human | Esophagus | ESCC | 2.60e-02 | 1.12e-01 | 0.0667 |
| 51147 | ING4 | LZE8T | Human | Esophagus | ESCC | 1.38e-07 | 2.42e-01 | 0.067 |
| 51147 | ING4 | LZE20T | Human | Esophagus | ESCC | 9.45e-05 | 2.17e-01 | 0.0662 |
| 51147 | ING4 | LZE24T | Human | Esophagus | ESCC | 2.59e-14 | 4.75e-01 | 0.0596 |
| 51147 | ING4 | P1T-E | Human | Esophagus | ESCC | 3.45e-05 | 3.83e-01 | 0.0875 |
| 51147 | ING4 | P2T-E | Human | Esophagus | ESCC | 1.11e-32 | 6.00e-01 | 0.1177 |
| 51147 | ING4 | P4T-E | Human | Esophagus | ESCC | 5.45e-18 | 4.43e-01 | 0.1323 |
| 51147 | ING4 | P5T-E | Human | Esophagus | ESCC | 3.61e-13 | 1.69e-01 | 0.1327 |
| 51147 | ING4 | P8T-E | Human | Esophagus | ESCC | 2.16e-24 | 3.71e-01 | 0.0889 |
| 51147 | ING4 | P9T-E | Human | Esophagus | ESCC | 2.81e-08 | 1.37e-01 | 0.1131 |
| 51147 | ING4 | P10T-E | Human | Esophagus | ESCC | 7.93e-29 | 5.22e-01 | 0.116 |
| 51147 | ING4 | P11T-E | Human | Esophagus | ESCC | 1.22e-04 | 2.29e-01 | 0.1426 |
| 51147 | ING4 | P12T-E | Human | Esophagus | ESCC | 2.88e-42 | 6.62e-01 | 0.1122 |
| 51147 | ING4 | P15T-E | Human | Esophagus | ESCC | 1.30e-16 | 3.21e-01 | 0.1149 |
| 51147 | ING4 | P16T-E | Human | Esophagus | ESCC | 1.95e-22 | 4.26e-01 | 0.1153 |
| 51147 | ING4 | P17T-E | Human | Esophagus | ESCC | 1.25e-05 | 3.36e-01 | 0.1278 |
| 51147 | ING4 | P19T-E | Human | Esophagus | ESCC | 2.96e-03 | 3.98e-01 | 0.1662 |
| 51147 | ING4 | P20T-E | Human | Esophagus | ESCC | 7.44e-26 | 5.71e-01 | 0.1124 |
| 51147 | ING4 | P21T-E | Human | Esophagus | ESCC | 7.87e-22 | 3.02e-01 | 0.1617 |
| 51147 | ING4 | P22T-E | Human | Esophagus | ESCC | 2.98e-51 | 9.56e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00183941 | Liver | Cirrhotic | peptidyl-lysine acetylation | 73/4634 | 169/18723 | 1.08e-07 | 3.07e-06 | 73 |
| GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
| GO:007233112 | Liver | Cirrhotic | signal transduction by p53 class mediator | 69/4634 | 163/18723 | 5.97e-07 | 1.30e-05 | 69 |
| GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
| GO:00064751 | Liver | Cirrhotic | internal protein amino acid acetylation | 65/4634 | 160/18723 | 6.66e-06 | 1.04e-04 | 65 |
| GO:00183931 | Liver | Cirrhotic | internal peptidyl-lysine acetylation | 64/4634 | 158/18723 | 8.75e-06 | 1.29e-04 | 64 |
| GO:001657011 | Liver | Cirrhotic | histone modification | 154/4634 | 463/18723 | 1.92e-05 | 2.57e-04 | 154 |
| GO:00165731 | Liver | Cirrhotic | histone acetylation | 61/4634 | 152/18723 | 1.97e-05 | 2.62e-04 | 61 |
| GO:0043967 | Liver | Cirrhotic | histone H4 acetylation | 31/4634 | 67/18723 | 1.03e-04 | 1.06e-03 | 31 |
| GO:003033012 | Liver | Cirrhotic | DNA damage response, signal transduction by p53 class mediator | 31/4634 | 72/18723 | 5.03e-04 | 4.00e-03 | 31 |
| GO:00427701 | Liver | Cirrhotic | signal transduction in response to DNA damage | 58/4634 | 172/18723 | 5.00e-03 | 2.59e-02 | 58 |
| GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
| GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
| GO:00183942 | Liver | HCC | peptidyl-lysine acetylation | 116/7958 | 169/18723 | 5.11e-12 | 2.23e-10 | 116 |
| GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
| GO:007233122 | Liver | HCC | signal transduction by p53 class mediator | 108/7958 | 163/18723 | 7.14e-10 | 2.23e-08 | 108 |
| GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
| GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ING4 | ICAF | Breast | IDC | TBP,CDKL5,AC025159.1, etc. | 6.19e-03 |  |
| ING4 | PLA | Lung | Healthy | LARP4,RPL36AL,CHCHD5, etc. | 7.85e-02 |  |
| ING4 | SPI | Oral cavity | EOLP | ZNF114,RP11-305K5.1,MME, etc. | 1.71e-01 |  |
| ING4 | NUER | Prostate | ADJ | AC007405.6,HCAR2,LSM11, etc. | 4.30e-02 |  |
| ING4 | NUER | Prostate | BPH | AC007405.6,HCAR2,LSM11, etc. | 2.51e-02 |  |
| ING4 | URO | Prostate | BPH | AC007405.6,HCAR2,LSM11, etc. | 5.33e-02 | |
| ING4 | URO | Prostate | Tumor | AC007405.6,HCAR2,LSM11, etc. | 1.59e-01 |  |
| ING4 | A.X | Stomach | Healthy | VAMP2,ZCRB1,ATP4B, etc. | 1.19e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ING4 | SNV | Missense_Mutation | c.349N>A | p.Glu117Lys | p.E117K | Q9UNL4 | protein_coding | tolerated(0.55) | benign(0.284) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ING4 | SNV | Missense_Mutation | novel | c.229N>C | p.Glu77Gln | p.E77Q | Q9UNL4 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ING4 | SNV | Missense_Mutation | c.463N>A | p.Pro155Thr | p.P155T | Q9UNL4 | protein_coding | tolerated(0.06) | possibly_damaging(0.616) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ING4 | SNV | Missense_Mutation | novel | c.662N>C | p.Trp221Ser | p.W221S | Q9UNL4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A00O-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ING4 | SNV | Missense_Mutation | c.470N>T | p.Thr157Ile | p.T157I | Q9UNL4 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ING4 | SNV | Missense_Mutation | novel | c.119N>A | p.Ala40Asp | p.A40D | Q9UNL4 | protein_coding | tolerated(0.38) | benign(0.024) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ING4 | SNV | Missense_Mutation | c.307N>T | p.Asp103Tyr | p.D103Y | Q9UNL4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ING4 | SNV | Missense_Mutation | novel | c.313N>T | p.Ala105Ser | p.A105S | Q9UNL4 | protein_coding | tolerated(0.12) | possibly_damaging(0.759) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ING4 | SNV | Missense_Mutation | novel | c.602G>A | p.Cys201Tyr | p.C201Y | Q9UNL4 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| ING4 | SNV | Missense_Mutation | c.497N>A | p.Arg166His | p.R166H | Q9UNL4 | protein_coding | tolerated(0.15) | benign(0.153) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |